Ameritas Advisory Services’s Ligand Pharmaceuticals LGND Stock Holding History

Ameritas Advisory Services’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2,275	Closed	-$167K	–	1685
2023 Q1	$167K	Buy	+2,275	New	+$162K	0.01%	822
2022 Q4	–	Sell	-3,727	Closed	-$200K	–	897
2022 Q3	$200K	Hold	3,727	–	–	0.01%	717
2022 Q2	$207K	Hold	3,727	–	–	0.01%	737
2022 Q1	$262K	Hold	3,727	–	–	0.01%	707
2021 Q4	$359K	Buy	+3,727	New	+$344K	0.01%	597

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

SDJVC

St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Ameritas Advisory Services's LGND Position: Q2 2023 in Review

Ameritas Advisory Services sold out of Ligand Pharmaceuticals (LGND) in Q2 2023, closing a stake of 2,275 shares — an estimated $167K sold.

Ameritas Advisory Services first reported a position in LGND in Q4 2021 and held it in 5 quarters. The position peaked at $359K in Q4 2021. 204 funds tracked by Wall St. Rank hold LGND as of Q2 2023.

Ameritas Advisory Services reported no remaining Ligand Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Ameritas Advisory Services sold 2,275 Ligand Pharmaceuticals shares in Q2 2023, an estimated $167K.
Ameritas Advisory Services first reported a position in Ligand Pharmaceuticals in Q4 2021 and held it in 5 quarters.
Ameritas Advisory Services's Ligand Pharmaceuticals position peaked at $359K in Q4 2021.
204 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2023.

Based on Ameritas Advisory Services's 13F filing for Q2 2023, filed 25 Jul 2023.